34.55

1.77% 0.60

Apogee Therapeutics Inc (APGE)

Overview News Price History Financials Discussions Forecast

Apogee Therapeutics Inc stock is traded at $34.55, with a volume of 656.35K. It is up +1.77% in the last 24 hours and down -12.44% over the past month. Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Previous Close:

$33.95

Open:

$34.59

24h Volume:

656.35K

Relative Volume:

1.27

Market Cap:

$1.97B

Revenue:

Net Income/Loss:

$-146.66M

P/E Ratio:

-12.54

EPS:

-2.7541

Net Cash Flow:

$-133.21M

1W Performance:

-5.45%

1M Performance:

-12.44%

6M Performance:

-28.54%

1Y Performance:

-0.14%

1-Day Range:

$32.54

$34.95

1-Week Range:

$32.46

$37.22

52-Week Range:

$32.46

$72.29

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

650-394-5230

Address

221 CRESCENT ST., WALTHAM

Employee

Twitter

Next Earnings Date

Latest SEC Filings

APGE's Discussions on Twitter

Compare APGE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APGE Apogee Therapeutics Inc	34.55	1.97B	0	-146.66M	-133.21M	-2.7541
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-24	Initiated	Canaccord Genuity	Buy
May-10-24	Initiated	BofA Securities	Buy
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc Stock (APGE) Latest News

12:44 PM

(APGE) Trading Report - Stock Traders Daily

12:44 PM

Feb 21, 2025

Interesting APGE Put And Call Options For October 17th - Nasdaq

Feb 21, 2025

Feb 20, 2025

Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month LowHere's What Happened - MarketBeat

Feb 20, 2025

Feb 15, 2025

Apogee Therapeutics (NASDAQ:APGE) Shares Down 7.1%Here's Why - MarketBeat

Feb 15, 2025

Feb 14, 2025

Apogee Therapeutics' (APGE) Buy Rating Reaffirmed at Guggenheim - MarketBeat

Feb 14, 2025

Feb 12, 2025

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga

Feb 12, 2025

Feb 11, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $608,700.00 in Stock - MarketBeat

Feb 11, 2025

Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 7.1% – What’s Next? - Defense World

Feb 11, 2025